DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice

Laboratory Investigation

Volumn 94, Issue 4, 2014, Pages 422-429

  Ojima, Ayako ^a   Matsui, Takanori ^a   Maeda, Sayaka ^a   Takeuchi, Masayoshi ^b   Inoue, Hiroyoshi ^c   Higashimoto, Yuichiro ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGE; aptamer; diabetes; melanoma; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; APTAMER; CD31 ANTIGEN; CELL NUCLEUS ANTIGEN; DNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; ANTIGENS, DIFFERENTIATION; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, IMMUNOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897388063     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.5     Document Type: Article

References (37)

1. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-567
2. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123
3. Rousseau M, Parent M, Pollak M, et al. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006;118:2105-2109
4. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007;16: 83-89
5. Emerging Risk Factors CollaborationSeshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
6. Rahbar S. The discovery of glycated hemoglobin: A major event in the study of nonenzymatic chemistry in biological systems. Ann NY Acad Sci 2005;1043:9-19
7. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann NY Acad Sci 1997;811: 115-127
8. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299
9. Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012;57:160-167
10. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009;16:845-858
11. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011;12:2096-2102
12. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996;222:700-705
13. Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol 2010; 739852; doi:10.1155/2010/739852
14. Abe R, Shimizu T, Sugawara H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004;122:461-467
15. Miki S, Kasayama S, Miki Y, et al. Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 1993;196:984-989
16. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193
17. Liu LS, Colegio OR. Molecularly targeted therapies for melanoma. Int J Dermatol 2013;52:523-530
18. Bock LC, Griffin LC, Latham JA, et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-566
19. Gragoudas ES, Adamis AP, Cunningham ET, et al. Group VISiONCT: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
20. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, et al. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011;106:539-547
21. Kaida Y, Fukami K, Matsui T, et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013;62:3241-3250
22. Matsui T, Nishino Y, Takeuchi M, et al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011;63:383-388
23. Yoshida Y, Yamagishi S, Matsui T, et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009;25:678-686
24. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen speciesmediated vascular endothelial growth factor expression. J Biol Chem 2006;281:20213-20220
25. Murata J, Saiki I, Makabe T, et al. Inhibition of tumor-Associated angiogenesis by sulfated chitin derivatives. Cancer Res 1991;51:22-26
26. Ishibashi Y, Matsui T, Takeuchi M, et al. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-Activated protein kinase. Horm Metab Res 2013;45:387-390
27. Kujawaski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid celldependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-3377
28. Park SJ, Kim HS, Yang HM, et al. Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. Arterioscler Thromb Vasc Biol 2004;24:885-891
29. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-Angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-357
30. Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004;165:1865-1874
31. Senger DR, van de Water L, Brown LF, et al. Vascular permeability factor in tumor biology. Cancer Metastasis Rev 1993;12:303-324
32. Torisu H, Ono M, Furue M, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85:182-188
33. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76:930-934
34. Vicioso L, Gonzalez FJ, Alvarez M, et al. Elevated serum levels of vascular endothelial growth factor are associated with tumor-Associated macrophages in primary breast cancer. Am J Clin Pathol 2006;125:111-118
35. Tsutsui S, Yasuda K, Suzuki K, et al. Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep 2005;14:425-431
36. Yamagishi Si, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272: 8723-8730
37. Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012;18: 1781-1788 Technology